ReviewInfection2024
Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective.
Review in Infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Integrating resistance biology, virulence networks, and precision therapeutics against multidrug-resistant Pseudomonas aeruginosa.Infection · 2026Review
- Genomic Characterization of Multidrug-ResistantMicroorganisms · 2026Article
- Pseudomonas aeruginosa: associated pathogenesis, epidemiology, resistance mechanisms, host response and emerging treatment strategies.Archives of microbiology · 2026Review
- Clinical distribution and drug resistance of carbapenem-resistant Pseudomonas aeruginosa infection in Eastern China from 2019 to 2024.BMC infectious diseases · 2026Article
- Assessment of the effect of culture components of clinical Pseudomonas aeruginosa isolates on vancomycin eradication of Staphylococcus aureus mature biofilms.BMC research notes · 2026Article
- Antimicrobial resistance patterns and carbapenemase gene distribution in pediatric Pseudomonas aeruginosa isolates: molecular and epidemiological insights from an Iranian referral center.BMC microbiology · 2026Article
- Molecular Mechanisms Underlying the Pathogenicity ofMedicina (Kaunas, Lithuania) · 2026Review
- Synergistic effects of meropenem, amikacin, and ciprofloxacin against carbapenem resistant Pseudomonas aeruginosa isolates.Scientific reports · 2026Article
- Antimicrobial Susceptibility and Fluoroquinolone Resistance Patterns ofAntibiotics (Basel, Switzerland) · 2026Article
- Identification of a novel natural compound inhibitor targeting AmpC β-lactamase to combat multidrug-resistantFrontiers in microbiology · 2026Article
- High-risk lineages shape the resistome and virulome of multidrug-resistantFrontiers in cellular and infection microbiology · 2026Article
- A Real-World Study on Medical Resource Consumption in Multidrug-Resistant Organism Infections Under the DRG Payment Model.Risk management and healthcare policy · 2026Article
- Sepsis in end-stage liver disease and acute-on-chronic liver failure: pathophysiology, diagnostic challenges, and pharmacological management.Frontiers in pharmacology · 2026Review
- Genetic and virulence analysis of carbapenem-resistant Pseudomonas aeruginosa in farm animals in Shandong province, China: implications for human health.BMC microbiology · 2025Article
- Quorum Sensing Inhibition by Sponge-AssociatedAntibiotics (Basel, Switzerland) · 2025Article
- The Esc(1-21)-1c Antimicrobial Peptide Inhibits a Specific Transcriptional Activator of the MexAB-OprM Efflux Pump inInternational journal of molecular sciences · 2025Article
- Coexistence of Multidrug Resistance and Hypervirulence-Associated Genes in Clinical Carbapenem-ResistantJournal of microbiology and biotechnology · 2025Article
- Antimicrobial Resistance Mechanisms in Carbapenem-ResistantPolish journal of microbiology · 2025Article
- Vancomycin Sensitization inACS infectious diseases · 2025Article
- Anti-QS Strategies AgainstMicroorganisms · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pseudomonas aeruginosa is one of the most common nosocomial pathogens and part of the top emergent species associated with antimicrobial resistance that has become one of the greatest threat to public health in the twenty-first century. This bacterium is provided with a wide set of virulence factors that contribute to pathogenesis in acute and chronic infections. This review aims to summarize the impact of multidrug resistance on the virulence and fitness of P. aeruginosa. Although it is generally assumed that acquisition of resistant determinants is associated with a fitness cost, several studies support that resistance mutations may not be associated with a decrease in virulence and/or that certain compensatory mutations may allow multidrug resistance strains to recover their initial fitness. We discuss the interplay between resistance profiles and virulence from a microbiological perspective but also the clinical consequences in outcomes and the economic impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.